Systemic Lupus Erythematosus
📧 Sign up to get email alerts when something new happens for Systemic Lupus Erythematosus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-01-07FDA Approved: AZATHIOPRINE SODIUM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves a supplemental application for azathioprine sodium from Hikma Pharmaceuticals USA Inc., updating the generic product's approval…
-
CLINICAL_TRIALS trial_result · 2021-01-05Clinical Trial Update: Triptorelin for Ovary Protection in Childhood Onset Lupus [Phase 2]
Phase 2 clinical trial evaluating triptorelin for ovary protection in childhood-onset systemic lupus erythematosus has completed; results po…
-
CLINICAL_TRIALS trial_result · 2020-12-28Clinical Trial Update: Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects [Phase 1]
Phase 1 trial assessing single-dose pharmacokinetics and safety of belimumab 200 mg IV and 200 mg subcutaneous via auto-injector in healthy …
-
CLINICAL_TRIALS trial_result · 2020-12-22Clinical Trial Update: A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) [Phase 3]
Phase 3 trial evaluating ocrelizumab for nephritis due to systemic lupus erythematosus was terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-12-19Clinical Trial Update: An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus [Phase 2]
Phase 2 extension study of GDC-0853 in moderate to severe active systemic lupus erythematosus has been terminated; results posted in 2020.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: A Phase II Study of M2951 in SLE [Phase 2]
Phase II study of M2951 in systemic lupus erythematosus was terminated; results were posted in 2020.
-
FDA approval · 2020-12-16FDA Approved: BENLYSTA — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for BENLYSTA (belimumab) submitted by GlaxoSmithKline LLC.
-
FDA approval · 2020-12-16FDA Approved: BENLYSTA — Supplemental Application (GlaxoSmithKline LLC)
The U.S. FDA has approved a supplemental application for Belimumab (Benlysta) from GlaxoSmithKline LLC.
-
CLINICAL_TRIALS trial_result · 2020-11-25Clinical Trial Update: Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches [Phase 2]
Phase 2 trial updating abatacept effects in systemic lupus erythematosus using integrated biologic and clinical approaches; results posted.
-
CLINICAL_TRIALS trial_result · 2020-11-25Clinical Trial Update: Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE) [NA]
A terminated clinical trial assessing dipyridamole for flare reduction in systemic lupus erythematosus; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-11-17Clinical Trial Update: Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus [Phase 4]
Phase 4 trial evaluating individualized rituximab to maintain remission in moderate to severe systemic lupus erythematosus.
-
CLINICAL_TRIALS trial_result · 2020-10-09Clinical Trial Update: Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis [Phase 1, Phase 2]
Phase 1/2 trial update for Cellcept (mycophenolate mofetil) in systemic lupus erythematosus with arthritis; results completed and posted.
-
CLINICAL_TRIALS trial_result · 2020-09-17Clinical Trial Update: A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN) [Phase 3]
Phase 3 trial evaluating two doses of ocrelizumab in active systemic lupus erythematosus was terminated; results were posted later.
-
CLINICAL_TRIALS trial_result · 2020-09-04Clinical Trial Update: Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children [Phase 4]
Phase 4 trial update on low-dose versus high-dose IV cyclophosphamide for proliferative lupus nephritis in children; study terminated.
-
CLINICAL_TRIALS trial_result · 2020-08-20Clinical Trial Update: Acthar Gel for Active Systemic Lupus Erythematosus (SLE) [Phase 4]
Phase 4 clinical trial update for Acthar Gel in active systemic lupus erythematosus (SLE) has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-19Clinical Trial Update: Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus [Phase 2]
Phase 2 trial evaluating low-dose interleukin-2 for systemic lupus erythematosus has completed.
-
CLINICAL_TRIALS trial_result · 2020-08-17Clinical Trial Update: Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) [Phase 2]
Phase 2 randomized trial evaluating withdrawal of mycophenolate mofetil in systemic lupus erythematosus was terminated; results posted in 20…
-
FDA approval · 2020-08-04FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for mycophenolate mofetil, a generic immunosuppressant used to prevent organ transplant rejecti…
-
CLINICAL_TRIALS trial_result · 2020-07-08Clinical Trial Update: A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE [Phase 4]
A Phase 4 crossover trial comparing RAYOS to immediate-release prednisone in systemic lupus erythematosus to assess fatigue and morning symp…
-
CLINICAL_TRIALS trial_result · 2020-07-07Clinical Trial Update: A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus [Phase 2]
Genentech's Phase 2 trial of GDC-0853 for moderate to severe systemic lupus erythematosus has completed, with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-04-28Clinical Trial Update: The Safety and Efficacy of Zishenqing in Subjects With Active Systemic Lupus Erythematosus [Phase 2, Phase 3]
A clinical trial update for Zishenqing in active systemic lupus erythematosus across Phase 2 and Phase 3 phases; status is unknown.
-
FDA approval · 2020-04-09FDA Approved: HYDROXYCHLOROQUINE SULFATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for hydroxychloroquine sulfate from Aurobindo Pharma Limited.
-
FDA approval · 2020-04-01FDA Approved: HYDROXYCHLOROQUINE SULFATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for hydroxychloroquine sulfate from Aurobindo Pharma Limited.
-
FDA approval · 2020-04-01FDA Approved: HYDROXYCHLOROQUINE SULFATE — Supplemental Application (Creekwood Pharmaceuticals LLC)
The FDA approved Creekwood Pharmaceuticals LLC's supplemental application for hydroxychloroquine sulfate, authorizing the continued marketin…
-
FDA label_change · 2020-03-31FDA Approved: HYDROXYCHLOROQUINE SULFATE — Supplemental Application (Ipca Laboratories Limited)
FDA approved a supplemental application for hydroxychloroquine sulfate from Ipca Laboratories Limited, resulting in changes to the drug's la…